MAR – Page 5 – Alligator Bioscience

2020-06-04

Regulatory

Alligator Bioscience and Scandion Oncology sign preclinical agreement to explore combination therapies for chemotherapy and immuno-oncology

Lund, Sweden, June 4, 2020 – Alligator Bioscience (Nasdaq Stockholm: ATORX) and Scandion Oncology (Spotlight, Sweden: SCOL), today announced ...

2020-06-01

Regulatory

Lund, Sweden, June 1, 2020 – Alligator Bioscience (Nasdaq Stockholm: ATORX), today announces that the company received an additional USD 0.5 ...

2020-05-29

Regulatory

Lund, Sweden, May 29, 2020 – Alligator Bioscience (Nasdaq Stockholm: ATORX), announces that the company today presents additional novel data ...

2020-04-27

Regulatory

Lund, Sweden, April 27, 2020 – Alligator Bioscience (Nasdaq Stockholm: ATORX), announces that the company today presents the status of the o ...

2020-04-23

Regulatory

Stronger focus on clinical projects "The focusing of our operations protects the company’s liquidity, but is also part of our long-term ...

2020-04-07

Regulatory

Lund, Sweden, 7 April 2020 – Alligator Bioscience (Nasdaq Stockholm: ATORX), announced today that the company has decided to increase its fo ...

2020-04-01

Regulatory

Lund, Sweden, 1 April 2020 – Alligator Bioscience (Nasdaq Stockholm: ATORX), announced today a temporary halt in the recruitment of new pati ...

2020-02-12

Regulatory

"2019 was the year when Alligator entered the clinical phase on a broad front. At the beginning of the year, we had one clinical project ...

2019-10-24

Regulatory

"We are now regaining the exclusive, global rights to develop and commercialize ADC-1013 and at the same time receive enough ADC-1013 su ...